Drug profile · INN
velaglucerase alfa
VPRIV
velaglucerase alfa (VPRIV) is a glucocerebroside hydrolytic enzyme. Associated with Takeda. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — velaglucerase alfa
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 7
- Data quality
- 0.89
Quick answer
velaglucerase alfa (VPRIV) is a glucocerebroside hydrolytic enzyme. Associated with Takeda. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocerebroside hydrolytic enzyme
Primary target: Glucocerebroside
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is velaglucerase alfa?
velaglucerase alfa (VPRIV) is a glucocerebroside hydrolytic enzyme. Associated with Takeda. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for velaglucerase alfa?
VPRIV is a marketed brand name for velaglucerase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of velaglucerase alfa?
velaglucerase alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.